These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 10509049)

  • 1. All-trans retinoic acid (ATRA) potentiates the in vitro inhibitory effects of IFN-alpha in parental (32D) and p210-bcr/abl transfected (LG7) murine myeloid cell lines.
    Russo D; Tell G; Marin L; Tiribelli M; Santucci MA; Pucillo C
    Haematologica; 1999 Oct; 84(10):955-7. PubMed ID: 10509049
    [No Abstract]   [Full Text] [Related]  

  • 2. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
    Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
    Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
    Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
    Brusa G; Benvenuti M; Mazzacurati L; Mancini M; Pattacini L; Martinelli G; Barbieri E; Greenberger JS; Baccarani M; Santucci MA
    Haematologica; 2003 Jun; 88(6):622-30. PubMed ID: 12801837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Competitive polymerase chain reaction as a method to detect the amplification of bcr-abl gene of chronic myeloid leukemia.
    Campanini F; Santucci MA; Pattachini L; Brusa G; Piccioli M; Barbieri E; Babini L; Tura S
    Haematologica; 2001 Feb; 86(2):167-73. PubMed ID: 11224486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changing concept of conventional therapy in chronic myelogenous leukemia].
    Ueda R
    Rinsho Ketsueki; 2000 Apr; 41(4):268-71. PubMed ID: 10846452
    [No Abstract]   [Full Text] [Related]  

  • 8. Cytogenetic characterization of a BCR-ABL transduced mouse cell line.
    Rudolph C; Hegazy AN; von Neuhoff N; Steinemann D; Schröck E; Stripecke R; Klein C; Schlegelberger B
    Cancer Genet Cytogenet; 2005 Aug; 161(1):51-6. PubMed ID: 16080957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of IFN-alpha combined with IL-6 on cell growth and related genes expression and apoptosis of bone marrow cells from CGL patients].
    Chen H; Tang L; Peng X; Luo Z; Luo S; Tan W
    Zhonghua Xue Ye Xue Za Zhi; 2000 Jul; 21(7):341-4. PubMed ID: 11877000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. All-trans retinoic acid potentiates the inhibitory effects of interferon alpha on chronic myeloid leukemia progenitors in vitro.
    Mahon FX; Chahine H; Barbot C; Pigeonnier V; Jazwiec B; Reiffers J; Ripoche J
    Leukemia; 1997 May; 11(5):667-73. PubMed ID: 9180290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia].
    Etienne G; Mahon FX
    Bull Cancer; 2001 Jul; 88(7):651-8. PubMed ID: 11495816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets.
    Cebo C; Voutsadakis IA; Da Rocha S; Bourhis JH; Jalil A; Azzarone B; Turhan AG; Chelbi-Alix M; Chouaib S; Caignard A
    Cancer Res; 2005 Apr; 65(7):2914-20. PubMed ID: 15805294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Modulation of adriamycin cytotoxicity on K 562 and K562adri cells by interferon alpha and/or all-trans-retinoic acid].
    Dufour P; Feugeas O; Bergerat JP; Oberling F
    Bull Cancer; 1994 Oct; 81(10):894-6. PubMed ID: 7734774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
    Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
    Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Influence of IFN-alpha and IFN-alpha combined with GM-CSF on expression of the genes related to cell apoptosis of MNCs from bone marrow in CML patients].
    Tang LJ; Chen HC; Peng XH
    Hunan Yi Ke Da Xue Xue Bao; 2000 Dec; 25(6):570-2. PubMed ID: 12516408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of hydroxyurea combined with interferon-alpha on growth and apoptosis-related oncogene expression of K562 cells].
    Chen H; Luo Z; Luo S
    Zhonghua Yi Xue Za Zhi; 2000 Aug; 80(8):606-9. PubMed ID: 11798827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New approach in the diagnosis and monitoring of treatment in chronic myelogenous leukemia].
    Matolcsy A
    Orv Hetil; 2004 Dec; 145(52):2603-9. PubMed ID: 15724695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
    Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV
    Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia].
    Ajima A; Takayama N; Hasegawa Y; Kojima H; Nagasawa T
    Gan To Kagaku Ryoho; 2003 Nov; 30(12):1997-9. PubMed ID: 14650975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
    Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
    Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.